세계의 뇌경색 시장 - 인사이트, 역학, 예측(2034년)

Key Highlights:

• Cerebral infarction, or ischemic stroke, occurs when a blood clot or atherosclerotic plaque blocks brain blood flow, causing tissue death. It presents abruptly with symptoms like unilateral weakness, speech issues, vision loss, or coordination problems, based on location.
• Secondary research indicates that ischemic strokes represent about 82% of all stroke cases in the United States, making them the most common stroke subtype. This high proportion highlights the significant burden of cerebral infarction compared to other forms such as hemorrhagic stroke, which occur far less frequently.
• Secondary analysis revealed that the highest number of cerebral infarction cases in Japan occurred among individuals aged over 50. This age group showed a significantly greater burden of the condition, indicating that the risk of cerebral infarction increases notably with advancing age in the Japanese population.
• The prevalence of cerebral infarction is expected to rise due to an aging population, increasing cases of hypertension, diabetes, obesity, and atrial fibrillation. Lifestyle factors such as poor diet, physical inactivity, and smoking also contribute significantly, along with improved diagnostic tools leading to better detection and reporting of stroke cases.
• Currently, there are no specifically approved drugs exclusively targeting cerebral infarction. This presents a strategic opportunity for emerging pharmaceutical companies to develop innovative, patent-protected therapies that address critical unmet clinical needs and offer a competitive edge within a treatment landscape largely dominated by generics and non-specific interventions.
• The therapeutic pipeline for cerebral infarction is notably limited, with only a few candidates like TYVALZI (sovateltide), BAY 3018250, and RNS60 under investigation. This highlights the pressing need for increased industry involvement, encouraging more companies to pursue innovative research and develop targeted therapies to address substantial unmet patient needs.
• The cerebral infarction market is currently dominated by generic therapies, with no novel, market-exclusive drugs available. This lack of innovation creates a space for advanced, targeted treatments that can offer differentiated value and improved clinical outcomes for patients.

DelveInsight's comprehensive report titled "Cerebral Infarction - Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of cerebral infarction. The report presents historical and projected epidemiological data covering total diagnosed prevalent cases of strokes, total diagnosed prevalent cases of cerebral infarction, Gender-specific diagnosed prevalent cases of cerebral infarction, Age-specific diagnosed prevalent cases of cerebral infarction. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in cerebral infarction. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Cerebral Infarction Overview

Cerebral infarction is a type of stroke caused by an interruption of blood flow to a part of the brain, leading to the death of brain tissue. It commonly results from a blocked artery due to a blood clot or atherosclerotic plaque and often presents with sudden neurological symptoms such as weakness, speech difficulties, or loss of coordination. The condition primarily affects older adults and is closely linked to risk factors like hypertension, diabetes, atrial fibrillation, and sedentary lifestyle.

Cerebral Infarction Diagnosis and Treatment Overview

Diagnosis of cerebral infarction is primarily based on neuroimaging, with non-contrast Computed Tomography (CT) scans used initially to rule out hemorrhage and confirm the presence of an ischemic event. Magnetic resonance imaging (MRI), particularly diffusion-weighted imaging (DWI), offers greater sensitivity in detecting early infarcts. Additional diagnostic tools such as CT angiography, MR angiography, and carotid Doppler studies help identify vascular occlusions or stenosis, while echocardiography and Electrocardiogram (ECG) can detect cardiac sources of emboli.

Treatment focuses on restoring cerebral blood flow and minimizing brain damage. Intravenous thrombolysis with tissue plasminogen activator (alteplase) is effective if administered within 4.5 hours of symptom onset. In eligible patients with large vessel occlusions, mechanical thrombectomy is performed within 6 to 24 hours. Long-term secondary prevention includes antiplatelet or anticoagulant therapy, lipid-lowering agents, blood pressure control, and lifestyle modifications. Rehabilitation therapies are essential for improving mobility, speech, and cognitive function, depending on the severity and location of the infarct.

Cerebral Infarction Epidemiology

The epidemiology section of the cerebral infarction market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining Key Opinion Leader (KOL) views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of cerebral infarction. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• Secondary research indicates that the prevalence of stroke in Spain is approximately 2.02% of the general population-significantly lower than the broader European average of 9.2%. This disparity may reflect differences in demographic profiles, risk factor management, suggesting potential areas for further investigation and public health optimization within Spain.
• Secondary analysis demonstrates that in Japan, individuals aged over 50 account for a significantly higher number of cerebral infarction cases compared to those under 50. This trend reflects the strong correlation between aging and increased stroke risk, emphasizing the need for targeted prevention strategies in older age groups.
• Insurance data from Germany reveal that approximately 81% of initial or recurrent cerebral insults were due to cerebral infarction, making it the predominant stroke subtype. Notably, the prevalence was higher among women than men, suggesting potential sex-based differences in stroke risk or healthcare-seeking behavior that warrant further investigation.
• Secondary analysis from Japan revealed that cerebral infarction predominantly affects individuals over 50, with females showing higher prevalence than males. This underscores age and sex as critical demographic drivers influencing disease burden and guiding targeted prevention and healthcare strategies.

Cerebral Infarction Market Outlook

The cerebral infarction therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

Cerebral infarction currently lacks disease-specific, market-exclusive therapies, with existing treatment approaches largely focused on acute reperfusion and secondary prevention using widely available generics. Management strategies such as thrombolysis, antiplatelet agents, and anticoagulants are effective but not curative, and none directly address the underlying vascular or neuroinflammatory pathology. This therapeutic limitation reflects a significant gap in innovation, as current options do not modify disease progression or offer neuroprotection.

The absence of targeted, disease-modifying treatments (DMT) highlights a critical opportunity for pharmaceutical development, particularly in designing novel agents that can extend the therapeutic window, improve outcomes, and reduce recurrence. As the global burden of cerebral infarction continues to grow with aging populations and rising vascular risk factors, advancing research toward mechanistically driven interventions remains essential for transforming clinical care and addressing unmet needs in this high-impact neurological condition.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the cerebral infarction market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Cerebral Infarction Drug Chapters

Emerging Drugs

TYVALZI (sovateltide): Pharmazz

Sovateltide is a first-in-class synthetic endothelin-B receptor agonist approved in India in May 2023 for treating acute cerebral ischemic stroke with Sun Pharmaceutical. It promotes neurovascular remodeling-enhancing angiogenesis, neurogenesis, and mitochondrial biogenesis-resulting in improved neurological outcomes when administered within 24 hours of stroke onset

• The drug is currently in the Phase III of clinical trial for the treatment of cerebral ischemic stroke in the US.
• In October 2023, a Special Protocol Assessment (SPA) agreement was finalized with the US Food and Drug Administration (FDA) for a Phase III clinical trial evaluating sovateltide in patients with acute cerebral ischemic stroke.

BAY 3018250: Bayer

BAY 3018250 is an investigational monoclonal antibody (mAb) developed by Bayer that targets alpha-2 antiplasmin (a2AP), a key inhibitor of fibrinolysis. By blocking a2AP, it aims to enhance the body's natural ability to dissolve blood clots, offering potential as a novel treatment for thrombotic conditions like acute ischemic stroke.

• The drug is currently in the Phase II of clinical trial for the treatment of acute ischemic stroke and expected Primary completion date is 3rd quarter of 2025.

RNS60: Revalesio

RNS60 is a proprietary oxygen-enriched saline formulation with proven cytoprotective, anti-inflammatory, and mitochondrial-supporting effects. It is being developed as an adjunctive therapy for acute ischemic stroke. Following encouraging Phase II results-demonstrating reduced brain tissue damage, improved functional recovery, and shorter hospitalization when administered within 24 hours-the company is advancing toward a Phase III trial.

• In July 2025, Revalesio reported the publication of results from the RESCUE Phase II trial evaluating RNS60 as an adjunctive therapy for acute ischemic stroke in the journal Stroke. The findings supported the progression of RNS60 into Phase III clinical development.

Cerebral Infarction Market Segmentation

DelveInsight's 'Cerebral Infarction - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future cerebral infarction market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Cerebral Infarction Market Size by Countries

The cerebral infarction market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM cerebral infarction market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Cerebral Infarction Market Size by Therapies

Cerebral infarction Market Size by Therapies is categorized into current and emerging markets for the forecast period 2025-2034.

Cerebral Infarction Drugs Uptake

This section focuses on the sales uptake of potential cerebral infarction drugs that have recently been launched or are anticipated to be launched in the cerebral infarction market between 2025 and 2034. It estimates the market penetration of cerebral infarction drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the cerebral infarction market.

The emerging cerebral infarction therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the cerebral infarction market.

Cerebral Infarction Market Access and Reimbursement

DelveInsight's 'Cerebral Infarction - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of cerebral infarction. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current cerebral infarction market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the cerebral infarction domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or cerebral infarction market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the cerebral infarction unmet needs.

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, Yale School of Medicine, US, Max-Planck-Institute for Heart and Lung Research, Germany, University of Burgundy, France, University of L'Aquila, Italy, Torrecardenas University Hospital, Spain; University of Edinburgh, United Kingdom; The University of Tokyo, Japan among others.

"As per KOL from the US, despite advancements in acute stroke care, cerebral infarction still lacks novel, disease-modifying therapies. Most current treatments focus on reperfusion and secondary prevention with generics. There's an urgent need for innovation targeting neuroprotection and regeneration, which could transform recovery potential, particularly for patients who present outside the limited thrombolytic window."

"Based on expert perspectives obtained from KOLs in the Germany, time remains the most critical factor in cerebral infarction outcomes. While imaging technologies have improved, pre-hospital delays and limited public awareness still hinder timely intervention. Expanding stroke-ready infrastructure, refining triage systems, and integrating AI-driven diagnostic tools could significantly reduce treatment delays and enhance outcomes in both urban and rural healthcare settings."

"According to insights shared by KOLs from Japan, with the global population aging rapidly, the prevalence of cerebral infarction is expected to rise significantly. Older adults often present with multiple comorbidities, complicating management and recovery. This demographic shift underscores the need for age-adapted stroke care strategies, especially in high-prevalence regions like Japan, where stroke remains a leading cause of long-term disability."

Note: Detailed assessment of KOL Views will be provided in the full report on cerebral infarction.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the cerebral infarction. Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Cerebral Infarction Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for cerebral infarction. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging cerebral infarction therapies.

Cerebral Infarction Report Insights

• Cerebral infarction Patient Population
• Therapeutic Approaches
• Cerebral infarction Pipeline Analysis
• Cerebral infarction Market Size and Trends
• Cerebral infarction Market Opportunities
• Impact of Upcoming Therapies

Cerebral Infarction Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Cerebral infarction Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Cerebral Infarction Market
• Cerebral infarction Drugs Uptake

Cerebral Infarction Report Assessment

• Cerebral infarction Current Treatment Practices
• Unmet Needs
• Cerebral infarction Product Profiles
• Cerebral infarction Market Attractiveness

Key Questions:

• How common is cerebral infarction?
• What are the key findings of cerebral infarction epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for cerebral infarction?
• What are the disease risk, burden, and unmet needs of cerebral infarction?
• At what CAGR is the cerebral infarction market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the cerebral infarction market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of cerebral infarction in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?
• How many companies are currently developing therapies for the treatment of cerebral infarction?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the cerebral infarction market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of market access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders (KOL) around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for cerebral infarction?

Treatment goals for cerebral infarction focus on restoring and preserving brain function, preventing stroke recurrence, and minimizing long-term disability. Supportive care includes blood pressure management, lipid control, and antiplatelet or anticoagulant use when appropriate. Monitoring recovery and addressing comorbidities like atrial fibrillation and diabetes are essential. While no disease-modifying therapy exists, ongoing research explores neuroprotection, vascular repair, and regenerative strategies to improve functional outcomes and quality of life.

2. What are the challenges in managing cerebral infarction?

Managing cerebral infarction is challenging due to the absence of disease-modifying therapies and the narrow therapeutic window for acute intervention. Delayed presentation often limits eligibility for reperfusion treatments. Overlapping symptoms with other neurological conditions can complicate diagnosis. Preventing recurrence while addressing comorbidities requires individualized care. Long-term management is further complicated by post-stroke disability and the need for multidisciplinary rehabilitation.

3. What are the key factors driving the growth of the cerebral infarction market?

The cerebral infarction market is expanding due to the rising global burden of stroke, aging populations, and increased prevalence of vascular risk factors such as hypertension and diabetes. Advances in imaging and acute care have improved detection and intervention. The lack of DMT and persistent unmet clinical needs are driving pharmaceutical innovation. Additionally, supportive healthcare policies and growing investment in neurovascular research are accelerating therapeutic development and market growth.

4. How will the cerebral infarction Market and Epidemiology Forecast Report benefit the clients?

The Cerebral Infarction Market and Epidemiology Forecast Report provides clients with strategic insights into disease prevalence, patient segmentation, and evolving market dynamics. It supports the identification of commercial opportunities, evaluation of treatment gaps, and informed planning for product development, market entry, or expansion. The report also helps stakeholders navigate regulatory landscapes, anticipate future trends, and make data-driven investment or policy decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Cerebral Infarction by Therapies in the 7MM in 2024
• 3.2. Market Share (%) Distribution of Cerebral Infarction by Therapies in the 7MM in 2034

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Types
• 7.3. Causes
• 7.4. Pathophysiology
• 7.5. Symptoms
• 7.6. Risk Factor
• 7.7. Diagnosis
  • 7.7.1. Diagnostic Algorithm
  • 7.7.2. Diagnostic Guidelines
• 7.8. Treatment and Management
  • 7.8.1. Treatment Algorithm
  • 7.8.2. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale:7MM
• 8.3. Diagnosed Prevalent Cases of Cerebral Infarction in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of Strokes
  • 8.4.2. Total Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.4.3. Gender-specific Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.4.4. Age-specific Diagnosed Prevalent Cases of Cerebral Infarction
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of Strokes
  • 8.5.2. Total Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.5.3. Gender-specific Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.5.4. Age-specific Diagnosed Prevalent Cases of Cerebral Infarction
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of Strokes
  • 8.6.2. Total Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.6.3. Gender-specific Diagnosed Prevalent Cases of Cerebral Infarction
  • 8.6.4. Age-specific Diagnosed Prevalent Cases of Cerebral Infarction

9. Patient Journey

10. Emerging Therapies

• 10.1. Key Cross Competition
• 10.2. TYVALZI (sovateltide): Pharmazz
  • 10.2.1. Drug Description
  • 10.2.2. Other Development Activities
  • 10.2.3. Clinical Trials Information
  • 10.2.4. Safety and Efficacy
  • 10.2.5. Analyst Views
• 10.3. BAY 3018250: Bayer
  • 10.3.1. Drug Description
• 10.32. Other Development Activities
  • 10.3.3. Clinical Trials Information
  • 10.3.4. Safety and Efficacy
  • 10.3.5. Analyst Views
• 10.4. RNS60: Revalesio
  • 10.4.1. Drug Description
  • 10.4.2. Other Development Activities
  • 10.4.3. Clinical Trials Information
  • 10.4.4. Safety and Efficacy
  • 10.4.5. Analyst Views

11. Cerebral Infarction

• 11.1. Key Findings
• 11.2. Market Outlook
• 11.3. Attribute Analysis
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions and Rebates
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptake
• 11.5. Total Market Size of Cerebral Infarction in the 7MM
• 11.6. Market Size of Cerebral Infarction by Therapies in the 7MM
• 11.7. The United States Market Size
  • 11.7.1. Total Market Size of Cerebral Infarction
  • 11.7.2. Market Size of Cerebral Infarction by Therapies
• 11.8. EU4 and the UK Market Size
  • 11.8.1. Total Market Size of Cerebral Infarction
  • 11.8.2. Market Size of Cerebral Infarction by Therapies
• 11.9. Japan Market Size
  • 11.9.1. Total Market Size of Cerebral Infarction
  • 11.9.2. Market Size of Cerebral Infarction by Therapies

12. Key Opinion Leaders' Views

13. Unmet Needs

14. SWOT Analysis

15. Market Access and Reimbursement

16. Appendix

• 16.1. Bibliography
• 16.2. Abbreviations and Acronyms
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight